Therefore, our aim was to deepen the knowledge of these serum biomarkers in AIS patients and to provide new data for potential clinical use by investigation of unknown relationship of GFAP and UCH-L1 levels with comprehensive imaging and clinical parameters. This evidence concerns the gene UCHL1 and androgen insensitivity syndrome.